Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Stimulates endogenous GH release through ghrelin receptor pathways without significant influence on cortisol or prolactin
DrugBank Online - BPC-157 Clinical Trials: Lists one Phase 1 trial (NCT02637284) for healthy volunteers
The largest Phase 2b trial (502 participants, 24 weeks) did not show statistically significant weight loss versus placebo
Copper peptide targeting dermal papilla cell activity AHK-Cu is a copper peptide investigated for its effects on dermal papilla cell proliferation and vascular endothelial growth factor (VEGF) expression in scalp and skin tissue
The peptides interaction with molecular pathways, particularly those involving nitric oxide and VEGF, underscores its unique capabilities in promoting tissue repair and healing
US$ 21.81
US$ 29.75
US$ 23.16
US$ 23.15
US$ 28.87
